"Should this be a press release from the company?"
No. It would not be good form to issue and opinion as it would probably be a violation of SEC rules.
They'll be more likely to issue a press release when it approved and that's slated by September. The OP is not really news.
If yahoo doesn't make it, I want to thank everyone that has contributed to this board that helped keep everyone up to date with relevant data and events.
It sure does make it easier to stay up to date with many eyes on the prize and sometimes opposing opinions.
On the up side if it stays quasi-broken, it's harder for the spammers to inject their trash.
"I've repeatedly gravitated to the hardest problems in organizations and untangled them"
I think he considers traffic to the website a problem to be rid of.
LOL. Yahoo is distraught with poor project management and subsequent QC before launch.
I would expect it to be highly accurate then. They know what biomarker to look for for specific issue.
I'm not a medical doctor but I'd say that it's highly dependent on what you want to look for. Once in the urine, you cannot be guaranteed that's it's in an identifiable form; but in most cases in just might be.
Do they follow up with a blood biopsy if the urine produces and unusual profile?
Their website does not reflect this but looking on clinicaltrials, they do have a P3. I'll have to consider it more closely.
interesting company. Nothing in P3 but have varlilumab opdivo combo. I think you're in for a long wait there. If they score a collaboration, I might get in. I won't touch it until well into P3 and after I study it more after they hit P3 and I see some publications from the P2 trials.
It's in a trial with sunitinib atm. There is a fair chance that which ever is inferior ( cf. Opdivo ) will quickly replace sunitinib.
Curious. It looks like it may be a good thing but I'm having trouble with the fact that their trigger was early april and they've still not released the analysis or any analysis. Then they presented only the P2 data at ASCO in early June...
What is your take on that?